Zoetis (NYSE:ZTS) Price Target Lowered to $180.00 at Stifel Nicolaus

Zoetis (NYSE:ZTS) had its price target decreased by research analysts at Stifel Nicolaus from $210.00 to $180.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 9.13% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Trading Down 0.6 %

ZTS stock traded down $0.96 during midday trading on Tuesday, reaching $164.94. The company’s stock had a trading volume of 529,098 shares, compared to its average volume of 1,905,701. Zoetis has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a fifty day simple moving average of $173.07 and a two-hundred day simple moving average of $180.47. The firm has a market capitalization of $74.42 billion, a price-to-earnings ratio of 31.00, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.36 EPS. On average, equities research analysts predict that Zoetis will post 5.9 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Hedge funds have recently added to or reduced their stakes in the business. Cherry Creek Investment Advisors Inc. lifted its position in Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after purchasing an additional 58 shares during the last quarter. Grove Bank & Trust lifted its stake in shares of Zoetis by 0.5% in the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after acquiring an additional 61 shares during the period. Hancock Whitney Corp boosted its holdings in shares of Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC increased its position in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC boosted its stake in Zoetis by 3.7% during the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after buying an additional 64 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.